EHA 2024: AstraZeneca's Calquence plus chemoimmunotherapy offers new standard for MCL [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
randomised, double-blind, placebo-controlled Phase III ECHO clinical trial were presented on AstraZeneca's Calquence (acalabrutinib). The trial tested the drug in combination with chemoimmunotherapy, bendamustine and Roche/Biogen's MabThera (rituximab) as first-line therapy for mantle cell lymphoma (MCL). The trial results suggest that this Calquence combination therapy could become a new standard-of-care (SOC) for older patients (65 years) with MCL, who are ineligible for autologous stem cell therapy, as it shows potential to extend survival for the first time. MCL is a rare and often severe form of non-Hodgkin lymphoma (NHL) that develops when B lymphocytes transform into malignant cells in the mantle zone of a lymph node and is frequently diagnosed in the late stages. MCL accounts for about 5% of NHL cases. According to GlobalData's epidemiology data, MCL has an annual incidence rate of one per 100,000 population across the seven major markets (the US, France, Germany, Italy, S
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Impact and implications of the $35 monthly price cap on asthma inhalers [Yahoo! Finance]Yahoo! Finance
- China Approves AstraZeneca's Tagrisso-Chemotherapy Combo Regime For Previously Untreated Lung Cancer Patients [Yahoo! Finance]Yahoo! Finance
- Corporate Reputation of Pharma in Canada, 2023/2024: The Views of 100 Canadian Patient Groups - Fair Pricing Policies, Transparency of Pricing, and Engaging Patients in R&D Among the Lowest-Scoring Indicators [Yahoo! Finance]Yahoo! Finance
- Tanium Plays Critical Role in Supporting AstraZeneca's Mission to Deliver Life-Changing Medicines [Yahoo! Finance]Yahoo! Finance
- AstraZeneca PLC (NASDAQ: AZN) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.MarketBeat
AZN
Sec Filings
- 6/25/24 - Form 6-K
- 6/25/24 - Form 6-K
- 6/18/24 - Form 6-K
- AZN's page on the SEC website